presented by martine piccart-gebhart at 2014 asco annual meeting
DESCRIPTION
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC). - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/1.jpg)
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 2: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/2.jpg)
TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 3: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/3.jpg)
Slide 3
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 4: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/4.jpg)
Slide 4
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 5: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/5.jpg)
Slide 5
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 6: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/6.jpg)
Slide 6
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 7: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/7.jpg)
Slide 7
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 8: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/8.jpg)
Primary Endpoint
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 9: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/9.jpg)
SECONDARY EndpointS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 10: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/10.jpg)
STAtiStical considerations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 11: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/11.jpg)
Current Analysis Plan
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 12: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/12.jpg)
Slide 12
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 13: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/13.jpg)
CONSORT TABLE
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 14: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/14.jpg)
Slide 14
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 15: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/15.jpg)
Distribution of the Stratification Factors by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 16: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/16.jpg)
Distribution of patient characteristics by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 17: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/17.jpg)
Slide 17
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 18: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/18.jpg)
DISEASE-FREE SURVIVAL (DFS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 19: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/19.jpg)
DFS BY Hormone Receptor Status
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 20: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/20.jpg)
DFS by Chemotherapy Timing
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 21: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/21.jpg)
OVERALL SURVIVAL (OS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 22: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/22.jpg)
DFS NON-INFERIORITY ANALYSIS<br />Note: Null hypothesis hazard ratio is 1.11
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 23: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/23.jpg)
Slide 23
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 24: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/24.jpg)
PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 25: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/25.jpg)
Slide 25
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 26: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/26.jpg)
MAIN DIFFERENCES IN AEs BY TREATMENT ARM
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 27: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/27.jpg)
CARDIAC SAFETY
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 28: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/28.jpg)
CONCLUSIONS (I)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 29: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/29.jpg)
CONCLUSIONS (II)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
![Page 30: Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022062520/56816016550346895dcf17a0/html5/thumbnails/30.jpg)
Acknowledgements
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting